The ABHI is the UK’s leading medical technology industry association with a community of over 260 members. ABHI champions the use of safe and effective medical technologies to deliver high quality patient outcomes. They engage with the NHS, government, regulators and other key stakeholders both here in the UK and abroad, in order to represent this industry. ABHI’s work focuses on UK Market, Economic Growth, Regulatory, Ethics and Compliance.
The Association of the British Pharmaceutical Industry (ABPI) represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
The ANSM is a public administrative body which acts on behalf of the French Government to ensure patient safety by conducting assessments and acting as a decision-making body in the field of the regulation of health products.
Alzheimer’s Research UK is the UK’s leading research charity aiming to defeat dementia. We power world class studies that give us the best chance of beating dementia sooner, our pioneering work focuses on prevention, treatment and cure. We are energising a movement across society to support, fund and take part in dementia research and aim to empower people across all generations through greater understanding of dementia. Together we have the power to defeat dementia.
To help get people thinking differently about dementia and fight the enduring misconception that the condition is just a by-product of age, we are encouraging people to #sharetheorange.
Asbestos.com are a US advocacy group that works to spread awareness of mesothelioma and asbestos-related diseases and provide free support to those currently suffering from them.
Please find below a list of services that can be found on asbestos.com:
• Monthly online support group where we discuss a variety of topics pertaining to either cancer patients or their caregivers
• On-staff doctor and nurse available to answer any medical-related questions
• 24-hour live chat support
• A team of Patient Advocates who work 1-on-1 with individuals to help them find local doctors, treatment centres and support groups
Please take a look at some of the information available at https://www.asbestos.com/treatment/.
The BIA is at the forefront of UK bioscience, serving as its voice, connecting individuals and organisations, from SMEs, including innovative start-ups, to multi-national companies, helping to shape the future of the sector.
Covers the field of biological sciences, including medicine. It indexes journal articles, meeting and conference reports, books and patents. Consider searching here for information on new research, pharmaceuticals and emerging technologies.
Blueteq is a web-based clinical decision support system that was implemented in 2015/16 as NHS England’s standard electronic contractual prior approval system, covering a range of high-cost drugs excluded from the drug tariff.
A clinical therapy resource of regularly updated evidence-based summaries, including a useful drug names table.
The Brazilian Health Regulatory Agency (Anvisa) is linked to the Ministry of Health as the coordinator of the Brazilian Health Regulatory System (SNVS), present throughout Brazil.
The Ministry of Health is the Federal Executive Branch responsible for the organisation and elaboration of plans and public policies aimed at promotion, prevention and health care in Brazil.
Publications which evaluate clinical evidence from diverse sources with information validated by a network of clinical experts. BNF Publications reflect current best practice as well as legal and professional guidelines relating to the uses of medicines.
Systematic reviews of social, behavioural and educational interventions.
Decisions about which medical devices and drugs to use are crucial to the quality and sustainability of health care in Canada. Access to evidence-based information is key to making informed decisions that harness the benefits of technology while getting the best value from every health dollar.
The federal health department is responsible for approving new drugs based on their safety, efficacy and quality.
The Institut national d’excellence en santé et en services sociaux was created on January 19, 2011. It succeeded the Conseil du médicament and the Agence d’évaluation des technologies et des modes d’intervention en santé (AETMIS). INESSS’s mission is to promote clinical excellence and the efficient use of resources in the health and social services sector. At the heart of the mission, INESSS assesses, in particular, the clinical advantages and the costs of the technologies, medications and interventions used in health care and personal social services. It issues recommendations concerning their adoption, use and coverage by the public plan, and develops guides to clinical practice in order to ensure their optimal use.
The Patented Medicine Review Board (PMPRB) regulates the pricing of patented medicines sold in Canada and reports on pharmaceutical trends.
The CDF is a centralised process that offers a route to funding in England for cancer medicines.
A clinical trials listing service and information source for the clinical trial industry.
CRD is a UK based research department located in the University of York that specialises in evidence synthesis, assembling and analysing data from multiple research studies to generate policy relevant research.
The Cumulated Index to Nursing and Allied Health Literature, CINAHL is also useful for coverage of the literature on occupational therapy, physiotherapy, and alternative medicine.
A database of clinical trials compiled by the US National Institutes of Health.
The official guide for conducting Cochrane systematic reviews.
Updated quarterly. The source for quality, systematic reviews of health care interventions; includes several databases. A subscription is required for full access (most health libraries have subscriptions; some countries have open access agreements with the publisher to make it freely available in their country).
DIT secure UK and global prosperity by promoting and financing international trade and investment, and championing free trade.
A devolved Northern Irish government department in the Northern Ireland Executive, with the aim to improve the health and social well-being of the people of Northern Ireland.
The Department of Health and Social Care (DHSC) is responsible for standards of healthcare in the UK, including the NHS. The Department sets the strategic framework for adult social care and influences local authority spending on social care. The Department is also responsible for promoting and protecting the public’s health, taking the lead on issues like environmental hazards to health, infectious diseases, health promotion and education, the safety of medicines, and ethical issues.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 37 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
A database covering international literature in the fields of biomedical sciences and pharmacology.
EMIG is the trade association in the UK that represents the interests of small to medium-sized pharmaceutical companies. EMIG member companies range from start-ups, whose prime focus is R&D, to highly developed businesses delivering essential products to patients, while continuing to invest heavily in the fight against disease. This rich blend of companies enables EMIG to uniquely understand and address the myriad challenges facing pharmaceutical innovation and commercialisation in the UK. EMIG is a democratic organisation, with one vote for each full member company, irrespective of size. EMIG policy is ratified by the membership at our AGM and reported on/refined at our Quarterly Meetings throughout the year. EMIG enables pharmaceutical SMEs to have an influence on the policies that determine success or failure in the UK.
Database of the Educational Resources Information Center includes health-related educational information.
EUCOPE provides a platform for discussion for pharmaceutical entrepreneurs. On a regular basis owners and CEOs of pharmaceutical companies and associations discuss solutions to improve the quality of life for patients and to strengthen the competitiveness of the European pharmaceutical industry.
The European Commission is the EU’s executive body. It represents the interests of the European Union as a whole and not individual countries.
The Commission’s main roles are to:
- propose legislation which is then adopted by the co-legislators, the European Parliament and the Council of Ministers
- (where necessary with the help of the Court of Justice of the EU)
- set a objectives and priorities for action, outlined yearly in the Commission Work Programme and work towards delivering them
- manage and implement EU policies and the budget
- represent the Union outside Europe (e.g. negotiating trade agreements between the EU and other countries)
The EMA is a decentralised agency of the European Union responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union.
This page lists the timetables for the submission, start and finish dates of procedures, as well as other interim dates and milestones that occur during the various procedures. Timetables are categorised according to the type of procedure (e.g. full applications, extensions and variations, as well as response timetables). The dates for submission, start of the procedure and plenary meetings of the Committee for Medicinal Products for Human Use (CHMP), the Pharmacovigilance Risk Assessment Committee (PRAC) and the Committee for Advanced Therapies (CAT) are generally fixed, but the other dates may be subject to adjustment until the CHMP reaches the adoption of the final opinion for the individual application. At the start of the procedure, the Agency will notify the applicant of the adopted final timetable in writing.
Haute Autorité de Santé (HAS) is an independent public scientific authority with financial autonomy. Its key purpose is to improve the quality of patient care and to guarantee equity within the healthcare system. It does this through the:
- assessment of drugs and medical devices
- certification of healthcare organisations and accreditations of doctors
- publication of guidelines (good practices, public health)
The Federal Joint Committee (G-BA) is the highest decision-making body of the joint self-government of physicians, dentists, hospitals and health insurance funds in Germany. It issues directives for the benefit catalogue of the statutory health insurance funds (GKV) for more than 70 million insured persons and thus specifies which services in medical care are reimbursed by the GKV. In addition, the G-BA specifies measures for quality assurance in inpatient and outpatient areas of the health care system.
A source of pricing information based on 17 organisations.
A source of national pricing information for 37 countries – states which category of price, for example reimbursement, ex-factory, patient
Formerly known as the Irish Medicines Board (IMB), the regulatory body in Ireland whose role it is to protect and enhance public and animal health by regulating medicines, medical devices and other health products.
HIS has a key role in supporting healthcare providers to make sure that their services meet these expectations and continually improve the healthcare the people of Scotland receive.
Listings of clinical trials registries in different medical specialties.
An international organisation promoting the science of pharmacoeconomics and health outcomes research Includes a section: Pharmacoeconomic Guidelines Around the World.
Institute for Quality and Efficiency in Health Care – The Institute for Quality and Efficiency in Healthcare is a German agency responsible for assessing the quality and efficiency of medical treatments, including drugs, non-drug interventions, diagnostic and screening methods, and treatment and disease management.
The Authority has a statutory remit to evaluate the clinical and cost-effectiveness of health technologies and provide advice arising out of the evaluation to the Minister for Health and Children and the Health Service Executive (HSE). The primary audience for health technology assessments (HTAs) conducted by the Authority is therefore decision makers within the publicly-funded healthcare system. It is recognised that the findings of any such HTA may also have implications for other key stakeholders in the Irish healthcare system. These include patient groups, the general public, clinicians, other healthcare providers, academic groups and the manufacturing industry.
The National Centre for Pharmacoeconomics conducts the health technology assessment (HTA) of pharmaceutical products for the Health Service Executive (HSE) in Ireland in collaboration with the HSE Corporate Pharmaceutical Unit (HSE-CPU). The aim of the centre is to promote expertise in Ireland for the advancement of the discipline of pharmacoeconomics through practice, research and education.
The ISRCTN registry is a primary clinical trial registry recognised by WHO and ICMJE that accepts all clinical research studies (whether proposed, ongoing or completed), providing content validation and curation and the unique identification number necessary for publication. All study records in the database are freely accessible and searchable.
Japan’s Ministry of Health, Labour and Welfare (MHLW) is the primary body that creates and implements standards for drugs and medical devices.
The National Institutes of Biomedical Innovation, Health, and Nutrition (NIBIOHN) was established in April 2015 by integrating the National Institute of Biomedical Innovation (NIBIO) and the National Institute of Health and Nutrition (NIHN). The goal of NIBIO is to support the development of innovative pharmaceutical and medical products in Japan, while the objective of NIHN is to help improve the health and well-being of the Japanese population through surveys and studies on hygiene, nutrition, and diet.
The Pharmaceutical and Medical Devices Agency (PMDA) is an independent regulatory agency established with the MHLW with the objective to protect the public health by assuring safety, efficacy and quality of pharmaceuticals and medical devices.
MAP Market Access provide an expert consulting service, offering product specific, one to one expert strategic advice on a consulting basis throughout the product lifecycle across the EU.
MAP offers an up to date, validated, web based subscription service, which acts as a ‘virtual’ expert to help you achieve pricing and reimbursement across the EU.
Medicines and Healthcare Products Regulatory Agency: The UK agency which regulates drugs and health technologies.
Mesothelioma Treatment Community is dedicated to the assistance and guidance of asbestos and mesothelioma victims around the world. We exist to not only inspire hope during these unbearable times but to also provide palliative care and comprehensive information through our website, resources, and educational videos. By being the largest resource for mesothelioma treatment options and complementary therapies for cancer, we are designed to help guide patients and their loved ones toward the answers and support they need to improve their quality of life, prognosis, and life expectancy.
Mesothelioma Trust Fund helps patients and families affected by mesothelioma cancer with medical costs, finding top mesothelioma doctors, understanding their diagnosis and information on asbestos trust funds. Their team of Patient Advocates are always available to answer your questions and guide you in your efforts to deal with the devastating medical and financial challenges associated with asbestos cancer.
Mesothelioma.net gives back to the cancer community by sponsoring The American Cancer Society, the MD Cancer Center, The Methodist Hospital System, and the Make a Wish Foundation. Our patient advocates are here to support you, answer your questions, provide you with resources and inform you about your financial options. We have helped hundreds of patients, and we’re here to help you and your loved ones today.
The National Cancer Institute (NCI) is the US government’s principal agency for cancer research and training. It includes the PDQ (Physician Data Query) database of cancer prevention, screening, genetics, diagnostic and treatment information, cancer clinical trials, statistics and patient guides.
PDQ, part of the Cancer.gov website, includes a database of ongoing and completed cancer trials, and information on cancer prevention, diagnosis and treatment.
The mission of the National Centre for PharmacoEconomics (NCPE) is to facilitate healthcare decisions on the reimbursement of technologies, by applying clinical and scientific evidence in a systematic framework, in order to maximise population wellness.
The NCPE is the Irish health technology assessment (HTA) body, assessing evidence for comparative effectiveness and cost-effectiveness of technologies for use by patients in Ireland. This is done through assessment of evidence submitted by manufacturers and independent systematic review. The NCPE also undertake research to inform national guidelines for HTAs.
Quality, accessibility and affordability are the cornerstones of the Dutch health care system. The Health Care Insurance Board has an important position in this system: we ensure that these pillars form a strong foundation. Thus we represent the interests of everyone under the Insurance Act and the Exceptional Medical Expenses Act are entitled to care.
Primary care people provide a snapshot of the current state of the NHS. They provide a quick overview, with easy to read infographics.
NHS England publishes statistics on a range of health and care subjects. Theses statistics are used to inform debate, decision making and research both within government and by the wider community.
Defers to and References UK Pharmascan. The NIHR Innovation Observatory aims to supply timely information to key health policy and decision-makers within the NHS about emerging health technologies that may have a significant impact on patients or the provision of health services in the near future. The scope of their activity includes pharmaceuticals, medical devices and equipment, diagnostic tests and procedures, therapeutic interventions, rehabilitation and therapy, and public health activities.
Access to many US NLM databases, including: ClinicalTrials.gov, MEDLINE/PubMed, LOCATORplus, MEDLINEplus, DIRLINE, Meeting Abstracts, TOXLINE Special and HSRProj.
WHO medicines, prices and funding – provides some source data for the prices of medicines in over 50 national organisations based in 35 countries.
Ovid helps researchers, librarians, clinicians, and other healthcare professionals find important medical information so that they can make critical decisions to improve patient care, enhance ongoing research, and fuel new discoveries. We offer a market-leading medical research platform of premium aggregated content and productivity tools that make it easy to quickly search information and make informed decisions on patient care, quality, and clinical outcomes.
The US National Library of Medicine (NLM)’s free search interface provides access to over 15 million citations covering biomedical literature back to the 1950’s in MEDLINE, PreMEDLINE (in process citations), OLDMEDLINE, and publisher supplied records.
The Systemic Anti-Cancer Therapy (SACT) dataset is the national mandatory collection of systemic anti-cancer therapy activity from all NHS England chemotherapy providers. This website contains all the latest information available from the SACT department within the National Cancer Registration and Analysis service of Public Health England.
Additional databases are available through commercial vendors, such as Dialog.
Mission: Promote coordination among the different agencies and units of Health Technology Assessment to inform decisions, based on more robust and reliable scientific knowledge, and ensure decisions are taken and implemented at various levels of the NHS. Objectives: Share resources in the development of various products and services Act as agent to ensure effective dialogue Promote joint projects and joint working.
Spanish Ministry of Health.
AEMPS is a regulatory agency within the Ministry of Health that oversees the quality, safety and efficacy of pharmaceuticals and medical technologies in Spain.
The Dental and Pharmaceutical Benefits Agency, TLV, is a central government agency whose remit is to determine whether a pharmaceutical product or dental care procedure shall be subsidised by the state. We also contribute to quality service and accessibility of pharmacies.
The Department of Health supports the Minister for Health and the Government by advising on the strategic development of the health system including policy and legislation and evaluating the performance of the health and social services.
The Ministry of Health in Turkey (Sağlık Bakanlığı) has a mission of continuously improving the health of the citizens of the country by preventing disease and providing a high level of healthcare to all citizens.
The Turkish Drug and Medical Device Institution (TITCK), (formerly known as the MoH General Directorate of Pharmaceuticals and Pharmacies, IEGM), is an affiliate of the Ministry of Health and is the responsible for the registration, marketing approval and authorisation, pricing, legal classification, and inspection of all human medicinal products.
The UK national office for HTA website has a useful database of published and in progress research and the full text of their assessment reports.
Extensive and wide range of resources including Guideline Finder, Protocol and Care Pathways, and Specialists Libraries to support healthcare-related decisions. http://www.evidence.nhs.uk/
On 1 April 2005 NICE joined with the Health Development Agency to become the new National Institute for Health and Clinical Excellence (also to be known as NICE). Guidance and technology appraisal reports, and patient information for the UK NHS.
SIGN provides evidence-based guidance on the diagnosis and management of specific conditions for the NHS in Scotland.
The remit of the Scottish Medicines Consortium (SMC) is to provide advice to NHS Boards and their Area Drug and Therapeutics Committees (ADTCs) across Scotland about the clinical and cost-effectiveness of all newly licensed medicines, all new formulations of existing medicines and new indications for established products (licensed from January 2002).
The AWMSG is the Welsh health technology appraisal (HTA) body, a statutory advisory Welsh Assembly-sponsored public body which aims to provide advice on medicines management and prescribing to the Welsh Government’s Minister for Health and Social Services in an effective, efficient and transparent manner.
Single Horizon Scanning Database for New Drugs in Development in the UK UK PharmaScan is a secure horizon scanning database populated with information on new medicines in development from up to three years before their launch in the UK or start of phase III clinical development, whichever is the earlier. This central repository provides up-to-date information, such as clinical trial and regulatory information, to national horizon scanning groups and approved NHS organisations that have a role in supporting NHS planning, or provide advice and guidance to the NHS. The resource will help ensure earlier and more effective decision making and faster uptake of innovative new medicines for the patients who need them.
Includes Science Citation Index Expanded, Social Sciences Citation Index, Current Contents Connect, and other databases. These databases cover literature in the fields of science and technology, social sciences and humanities.